Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Inflammatory arthritis
•
Orthopedics
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
Related Questions
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
What is your approach to differentiating and managing DMARD-induced nodulosis (induced by methotrexate or leflunomide for example) from "de novo" RA nodules in seropositive RA patients?
Can inflammatory arthritis develop in patients with a history of chronic hepatitis B?
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
What is the maximum dose of leucovorin that you use with methotrexate?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Do you have any experience with compounded iguratimod either as adjunctive therapy or monotherapy for rheumatoid arthritis, Sjogrens, or axial spondyloarthropathy?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
